Avirup Guha, Director of Cardio-Oncology at Georgia Cancer Center, shared a post on LinkedIn:
“Cardio-oncology trials should measure more than ejection fraction.
I was joined by sara hurvitz coauthor and divisionchief University of Washington hemeonc to discuss how patient-reported symptoms and function complement objective CV endpoints – and why standardized definitions matter.”
Title: Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association
Authors: Ana Barac, Avirup Guha, Thomas R. Fleming, Marc Bonaca, Paaladinesh Thavendiranathan, Anita Deswal, Laleh Amiri-Kordestani, Vishal Bhatnagar, Raul Cordoba, Sara Hurvitz, Alex A. Adjei, Neeraj Agarwal
Read The Full Article
